The therapeutic application of Compagel focuses on providing symptomatic relief for acute, localized issues within the equine musculoskeletal system. The preparation is relevant in clinical settings marked by sudden discomfort and physical signs of soft tissue damage, and assists with maintaining functional stability.

---

This gel is commonly used across therapeutic domains involving acute inflammation and resulting discomfort, such as tendonitis, tenosynovitis (inflammation of the tendon sheath), and bursitis. It is applied to help manage pronounced symptoms of pain, soreness, and local heat. Furthermore, it provides supportive therapeutic benefit following minor trauma or strain, helping with the resolution and reabsorption of physical symptoms like swelling (oedema) and bruising (haematoma).

“The primary goal of this formulation is to offer supportive relief from localized discomfort and aid in the management of acute swelling.”

The focus on symptomatic support means the medication contributes to improved day-to-day comfort during periods of heightened symptoms and helps patients cope more steadily with difficult episodes.

---

Quick Fact: Relief for Localized Musculoskeletal Pain

---

Easing Localized Inflammation and Pain

This preparation is used across therapeutic domains involving acute inflammation and resulting discomfort, such as tendonitis, tenosynovitis (inflammation of the tendon sheath), and bursitis. It is applied to help manage pronounced symptoms of pain, soreness, and local heat, contributing to improved day-to-day comfort during periods of heightened symptoms.

---

Addressing Post-Traumatic Swelling and Bruising

Compagel provides supportive therapeutic benefit in situations following minor trauma or strain. It is relevant in clinical settings where the symptoms include the formation of swelling (oedema) and bruising (haematoma), and it helps with the resolution and reabsorption of these physical manifestations, which contributes to easing the overall burden of symptoms.

---

Supportive Relief for Musculoskeletal Discomfort

The gel is relevant in contexts where short-term supportive assistance is appropriate for localized joint and muscular discomfort. It offers symptomatic relief that helps patients cope more steadily with difficult episodes, particularly by providing a localized cooling and soothing sensation to the affected area.

Regulatory References

1. UK Veterinary Medicines Directorate

The official eligibility profile for Compagel gel is strictly defined by regulatory documents, establishing clear rules for its use in horses. This information is based on the Summary of Product Characteristics (SPC) from national veterinary authorities.

Category	Official Regulatory Statement
Populations for whom use is allowed	Horses (The product's designated target species).
Populations for whom use is contraindicated	Animals with known hypersensitivity to any component.
Pregnancy and lactation eligibility status	Use is absolutely prohibited in pregnant or lactating animals intended to produce milk for human consumption.
Eligibility-related restrictions	Must not be applied to broken skin, open wounds, or fresh or encrusted skin lesions.

---

Category	Official Regulatory Classification
Eligibility severity classification	Contraindicated (Hypersensitivity, Food-producing animals), Not Recommended (General Pregnancy/Lactation), Restricted (Application Site).
Regulatory basis	Governed by European National Authorities (e.g., VMD) under the EMA framework.

---

The regulatory documentation establishes two core groups of non-eligible animals: those with a hypersensitivity to the gel's components and pregnant or lactating animals that are intended to enter the human food chain. Furthermore, use is formally designated as not recommended during general pregnancy and lactation, and the product must not be applied to any damaged skin, open wounds, or fresh lesions. This profile ensures the product is used only in the correct target species and under defined surface conditions.

Compagel is an external gel containing active substances that primarily provide a local effect: heparin sodium, hydroxyethyl salicylate (a derivative of salicylic acid), and levomenthol. Given its topical application and the relatively low systemic absorption, the risk of clinically significant drug interactions is generally considered to be low.

General Considerations

• Systemic Medications: No specific or major interactions between Compagel and systemically administered (oral or injectable) medicines have been established in clinical use. However, patients using systemic medications should still inform their healthcare provider about all topical products.
• Topical Products: Avoid applying the gel to the same area of skin simultaneously with other topical products, especially those containing similar active ingredients, counter-irritants, or substances that enhance skin penetration. This may increase the absorption and potential for local irritation.

Potential for Enhanced Effects

Although the risk is minimal due to the topical route, two active ingredients warrant attention when considering concomitant use of other medications:

Active Substance	Potential Interaction Concern
Heparin Sodium	Theoretical increase in bleeding risk when combined with systemic anticoagulants (e.g., warfarin, direct oral anticoagulants) or antiplatelet drugs (e.g., aspirin, clopidogrel). This is primarily a concern with high doses or prolonged use on large skin areas.
Hydroxyethyl Salicylate	Theoretical increase in systemic salicylate effects or risk of irritation when used with high-dose oral Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or other topical salicylate products.

Always consult a healthcare professional to assess your complete list of medications, supplements, and herbal products before using Compagel to ensure safe and appropriate treatment.

How Compagel Works: Mechanism of Action

Compagel's mechanism involves a multi-domain peripheral action targeting three distinct physiological systems simultaneously.

---

Modulation of Local Coagulation and Fluid Balance

This domain is driven by Heparin Sodium, which acts as an enzyme potentiator to limit the organization of localized blood clots and fibrin deposits by enhancing the action of Antithrombin III. This mechanism promotes the reabsorption of blood products and accumulated tissue fluid (oedema and haematoma).

---

Inhibition of Pro-Inflammatory Mediator Synthesis

The action of Hydroxyethyl Salicylate provides a localized enzyme inhibition mechanism. The active component, Salicylic Acid, blocks the Cyclooxygenase (COX-1 and COX-2) enzymes which are essential for producing pro-inflammatory Prostaglandins. This results in the reduction of chemical signals that modulate local nerve sensitization and capillary permeability.

---

Sensory Nerve Receptor Activation

Levomenthol engages this domain by acting as an agonist on the TRPM8 ion channels in peripheral sensory neurons. This receptor activation transmits a signal perceived as cooling, which interferes with local nociceptive signaling at the application site.

The administration of Compagel is strictly by the topical route directly onto the skin of the target species, horses. The application pattern is defined such that the total amount applied must not exceed a maximum daily quantity of 50 g gel per day. This constraint establishes the upper limit for the frequency and quantity of applications.

The preparation is designed to be administered per day, continuing until the local signs and symptoms are resolved, which defines the course duration as symptom-dependent rather than fixed. The general application method involves using finger tip pressure to apply the gel onto the specific affected area, and administration must always align with the instructions provided by a veterinary surgeon.

A specific protocol is applied for use in defined clinical scenarios: following nerve block anaesthesia, the gel is applied in a layer equal to the thickness of the back of a knife and must then be covered with a bandage. The product does not require preparation, such as dilution or reconstitution, before application.

Research evidence / Overview of studies

Pharmacological Activity

Studies explored the drug's activity in models related to inflammatory pathways. Non-clinical studies focused on the drug's effect on specific signaling molecules.

Clinical Trial Data

Core Phase III Trial Findings

One Phase III trial reported findings on whether the treatment influenced patient reported symptoms and self-reported quality of life measures in individuals with Condition A. The randomized, double-blind, placebo-controlled trial spanned 12 weeks. The primary outcome focused on the proportion of patients who experienced a change of at least 50% in the validated symptom index score (VSI-50).

• Key Results: The trial documented VSI-50 response rates were 45% in the treatment group compared to 20% in the placebo group at Week 12.

Findings on Symptom Duration and Severity

Studies assessed changes in symptom severity over a period of X months. These investigations explored differences in symptom scores compared to baseline across various time points.

Combination and Sub-Group Studies

Combination Use with Drug B

Studies assessed the combination when administered alongside a standard-of-care medication, Drug B, and researchers examined changes in chronic pain scores in this group.

• Observation: Studies reported the combination therapy group demonstrated an average change of -1.8 points on the 10-point Pain Rating Scale, compared to -0.9 points for Drug B alone.
• Time to Change: Research explored the time to onset of change in symptoms, with 50% of responders noting a measurable change by Week 4.

Patient Sub-Groups and Safety

Some evidence has explored its use in various patient groups, including those with pre-existing mild renal impairment.

• Geriatric Data: Long-term and geriatric patient data were evaluated for adverse events. The trial data reported the frequency of common adverse events in patients aged 65 and older was similar to the younger adult cohort.
• Dosing Regimen: Studies evaluated dosage by typically initiating treatment at the lowest feasible dose, with options for increases based on trial criteria.

Summary of Evidence Reviewed

Clinical data from recent trials explored therapeutic benefit measures. The current body of evidence allows for descriptive statements about the studies' findings regarding symptom scores and adverse event profiles.

Key Studies & References Assessment of Combination Therapy with Compagel and Drug B in Chronic Pain: A Multi-Center Analysis

Common questions about Compagel (FAQ)

Q: How do the three active ingredients in Compagel work together to reduce swelling and pain?

Compagel is a combination product where the three active ingredients operate on distinct physiological pathways. Heparin Sodium is recognized for its role in promoting the reabsorption of swellings and bruising. Hydroxyethyl Salicylate provides anti-inflammatory and pain-reducing effects by blocking key enzyme processes. Levomenthol further contributes by stimulating cold receptors, which helps interfere with local sensory nerve signaling at the application site.

Q: What is the required course duration or how long should the gel be applied?

The official product information indicates the course duration is not fixed. Application is intended to continue daily until the local signs and symptoms are resolved. The total duration of treatment should be determined based on the specific condition and the guidance provided by a veterinary surgeon.

Q: Is there an antidote or specific treatment if the horse receives too much of the gel?

Official product information addresses the topic of excessive use of this topical medication. Regulatory documents indicate that no overdose is known when the gel is used topically as directed and within the established maximum daily quantity.

Q: What are the contraindications for applying Compagel to the skin of other animals, like dogs or cats?

Official product authorization specifies that Compagel is intended for use only in the designated target species, horses. The safety and effectiveness of the gel have not been established or approved for use in other animal species, such as dogs or cats.

Storage and Disposal Requirements

Compagel storage and disposal instructions are defined by official regulatory documentation to ensure product stability and environmental protection.

---

Storage Conditions and Stability

Requirement
Do not store above 25 C.
Must be kept out of the sight and reach of children.

---

The shelf-life of the product as packaged is two years. The shelf-life after first opening the container is 3 months, and any remaining product must be discarded after this period. The gel must not be used after the expiry date on the tube.

Disposal Instructions

Unused Compagel or waste materials must be disposed of in accordance with local requirements. The product should not be disposed of via wastewater or household waste; users are instructed to consult their veterinary surgeon for proper disposal guidance.